Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Allevinix** is a veterinary brand name for a 50 mg/ml flunixin meglumine solution for injection, authorized for use in cattle, pigs, and horses primarily in the UK and EU. As a non-steroidal anti-inflammatory drug (NSAID), it inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby alleviating inflammation, pain, and fever. It is indicated for conditions such as respiratory disease (with anti-infective therapy), mastitis, lameness, musculo-skeletal disorders, visceral pain like colic, post-partum issues, gastro-intestinal disorders, and post-dehorning pain. Developed and marketed by Ceva Sante Animale as a generic application, it offers flexible intramuscular (IM) or intravenous (IV) administration, fast onset (peak plasma in ~30 minutes post-IM), and short withdrawal periods (e.g., 24-36 hours for milk in cattle).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allevinix.